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A Computer Simulation Approach to
Assessing Therapeutic Intervention Points for the
Prevention of Cytokine-Induced Cartilage Breakdown
C. J. Proctor,1 C. Macdonald,2 J. M. Milner,2 A. D. Rowan,1 and T. E. Cawston1
Objective. To use a novel computational approach
to examine the molecular pathways involved in cartilage
breakdown and to use computer simulation to test
possible interventions for reducing collagen release.
Methods. We constructed a computational model
of the relevant molecular pathways using the Systems
Biology Markup Language, a computer-readable format
of a biochemical network. The model was constructed
using our experimental data showing that interleukin-1
(IL-1) and oncostatin M (OSM) act synergistically to
up-regulate collagenase protein levels and activity and
initiate cartilage collagen breakdown. Simulations were
performed using the COPASI software package.
Results. The model predicted that simulated in-
hibition of JNK or p38 MAPK, and overexpression of
tissue inhibitor of metalloproteinases 3 (TIMP-3) led to
a reduction in collagen release. Overexpression of
TIMP-1 was much less effective than that of TIMP-3
and led to a delay, rather than a reduction, in collagen
release. Simulated interventions of receptor antagonists
and inhibition of JAK-1, the first kinase in the OSM
pathway, were ineffective. So, importantly, the model
predicts that it is more effective to intervene at targets
that are downstream, such as the JNK pathway, rather
than those that are close to the cytokine signal. In vitro
experiments confirmed the effectiveness of JNK inhibi-
tion.
Conclusion. Our study shows the value of com-
puter modeling as a tool for examining possible inter-
ventions by which to reduce cartilage collagen break-
down. The model predicts that interventions that either
prevent transcription or inhibit the activity of collage-
nases are promising strategies and should be investi-
gated further in an experimental setting.
Rheumatoid arthritis and osteoarthritis are both
characterized by loss of extracellular matrix (ECM) in
the cartilage of articular joints. Cartilage is maintained
by chondrocytes that secrete ECM components, such as
collagen and aggrecan. In both diseases, joint damage
occurs as the cartilage matrix is destroyed by proteinases
that are up-regulated by a variety of different stimuli.
While ADAMTS-4 and ADAMTS-5 are mainly respon-
sible for the degradation of aggrecan, collagen is de-
graded by the collagenases (matrix metalloproteinase
1 [MMP-1] and MMP-13). Tissue inhibitor of metallo-
proteinases (TIMPs) are endogenous inhibitors of
MMPs, and TIMP-3 can also inhibit ADAMTS (1,2).
Aggrecan breakdown is reversible, but the irreversibility
of collagen release makes its prevention key for devel-
oping effective therapies for arthritis. This requires
detailed knowledge of the mechanisms involved in col-
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lagen breakdown. We have previously used cell and
organ systems to examine the pathways that lead to the
up-regulation of the collagenases following the addition
of cytokines to chondrocytes (3–5). Since collagenases
are initially synthesized in an inactive form, they require
activators to be present in order to effect collagen
release (6).
In our in vitro models, we have used combina-
tions of interleukin-1 (IL-1) and oncostatin M (OSM) to
promote cartilage collagen breakdown; neither cytokine
alone reproducibly leads to collagen cleavage (5–7). IL-1
is a proinflammatory cytokine that binds to the IL-1
receptor (IL-1R) and recruits IL-1R–associated kinase
(IRAK) proteins, which are phosphorylated. This leads
to recruitment of tumor necrosis factor receptor–
associated factor 6 (TRAF6) proteins, which phosphor-
ylate JNK. Activated JNK then phosphorylates c-Jun,
which forms homodimers or binds c-Fos to form het-
erodimers, which form part of the activator protein 1
(AP-1) transcription factor. The c-Jun homodimers have
low affinity for DNA (8), whereas AP-1, which is
composed of c-Fos and c-Jun, has high affinity for the
promoter regions of many target genes, such as MMPs,
phosphatases, ADAMTS, and the transcription factor
Sp-1. Sp-1 inhibits TIMP-1 transcription by binding to a
repressive element in the first intron of TIMP-1 (9).
Messenger RNA (mRNA) for c-Fos has a very short
half-life, is not expressed under normal cellular condi-
tions, and is only weakly expressed after stimulation with
IL-1. Therefore, IL-1 stimulation alone will favor the
formation of c-Jun homodimers, leading to lower levels
of up-regulation of AP-1 target genes than those with
IL-1 plus OSM stimulation.
OSM has antiinflammatory and proinflammatory
roles, with signaling primarily via the JAK/STAT path-
way (10). There is evidence that p38 phosphorylates
c-Fos to enhance its transcriptional activity (11). OSM
synergizes with IL-1 to increase the expression of MMPs
in chondrocytes (12), and since STAT proteins do not
bind MMP promoters in chondrocytes, this synergy
occurs through STAT stimulation of c-Fos expression,
leading to changes in AP-1 composition that regulate
MMP expression. It should be noted that c-Fos is
regulated at the transcriptional level, whereas c-Jun is
regulated post-translationally via phosphorylation. The
pathways involved in collagen release are thus complex,
involving cross-talk between different pathways and
many feedback loops.
It has become increasingly recognized that sys-
tems modeling approaches are required to complement
experimental work, and computational models have
been widely used in the fields of cancer, cardiovascular
diseases, and neurodegeneration; to date, this approach
is not established in the study of musculoskeletal dis-
eases (13–15). In this study, we used our existing in vitro
data from cell and organ culture models to construct an
in silico model of cartilage collagen breakdown following
stimulation with IL-1 and OSM combinations. Our aim
was to demonstrate how computational models can be
developed using current knowledge of the system to
highlight important gaps in knowledge, to test new
hypotheses, and to predict outcomes for different ther-
apeutic approaches.
METHODS
Model construction. The model contains 3 separate
submodels: the first describes the IL-1/JNK signaling pathway,
the second describes the OSM/STAT-3 signaling pathway, and
the third describes proMMP activation and the release of
aggrecan and collagen (see Supplementary Figures 1–3, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38297/abstract). This
modular approach allows new components to be easily added
and allows existing modules to be reused in further models.
The models were encoded in the Systems Biology Markup
Language (SBML), a computer-readable format for represent-
ing biochemical networks (16), using the Python tool SBML-
shorthand (17). The integrated model was deposited in the
BioModels Database (18) and assigned the identifier
MODEL1305280001. The main features and assumptions of
the model are described below. Full details of the model
species, parameters, and reactions are given in Supplementary
Tables 1–3 (available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38297/abstract).
IL-1 signaling pathway module. This module contains
details of the signaling pathway from IL-1 binding to its
receptor, leading to a cascade of phosphorylation events via
IRAK-2, TRAF6, JNK, p38, and finally c-Jun. We assumed
that phosphorylated c-Jun can form dimers that have low
transcriptional activity for the following target genes: c-Jun,
MMP-1, MMP-3, MMP-13, ADAMTS-4, protein phosphatase
4 (PP-4), dual-specificity protein phosphatase 16 (DUSP-16),
and MAPK phosphatase 1 (MKP-1). We also included basal
transcription of c-Jun, TIMP-1, and TIMP-3, which does not
involve c-Jun. For species with available experimental data for
both the mRNA and protein levels, we included transcription
and translation reactions (c-Jun, MMPs, and ADAMTS-4);
otherwise, we modeled protein synthesis as one reaction
(DUSP-16, PP-4, and MKP-1).
OSM signaling pathway module. This module contains
details of the signaling pathway from OSM binding to its
receptor (OSMR), leading to phosphorylation of JAK-1 and
STAT-3. We assumed that pSTAT-3 can be transported to the
nucleus, where it may transcribe c-Fos, receptor-type protein
tyrosine phosphatase T (PTPRT), and suppressor of cytokine
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signaling 3 (SOCS-3). If pSTAT-3 is dephosphorylated in the
nucleus, it is transported back to the cytoplasm. SOCS-3 binds
to OSMR in competition with OSM and so provides a negative
feedback loop by which to stop this signaling pathway. The
c-Fos protein is phosphorylated by p38 and dephosphorylated
by either DUSP-16 or an unspecified phosphatase. Phosphor-
ylated c-Fos can reversibly bind to phosphorylated c-Jun to
form a complex, which represents the AP-1 transcription
factor. We include transcription of the following genes by
c-Fos/c-Jun heterodimers: c-Fos, c-Jun, MMP-1, MMP-3,
MMP-13, ADAMTS-4, DUSP-16, PP-4, MKP-1, Sp-1,
TIMP-1, and TIMP-3. PP-4 binds to TRAF6 to prevent the
binding of TRAF6 to IRAK-2 and so provides an additional
negative feedback loop to stop OSM signaling.
Activation of proMMPs and degradation of aggrecan
and collagen module. We assumed that proMMP-1 and
proMMP-3 are activated by a generic activator (MMP activa-
tor) and that MMP-3 also activates proMMP-1 and proMMP-
13. Initially, aggrecan is bound to collagen and behaves as a
complex, since it has been shown that aggrecan protects
collagen from degradation. We modeled aggrecan degradation
by ADAMTS-4, which results in an unprotected collagen
molecule. Free collagen can then be degraded by MMP-1 or
MMP-13. We assumed that MMP-13 has greater activity at
cleaving collagen than MMP-1 but that there are much higher
levels of MMP-1 compared to MMP-13, which means that both
collagenases are important for collagen release (19). We also
assumed that activated pools of MMPs are removed with a
half-life of about 30 hours. It has been shown that TIMP-1 is
more effective at inhibiting MMPs whereas TIMP-3 mainly
inhibits ADAMTS (1), and this assumption is included in our
model.
Parameter values. Parameters for the signaling path-
ways were chosen to fit experimental data where available. For
example, we used published data on receptor binding affinities
(20,21), time course data on kinase activity (22,23), data on
phosphorylation and localization of STAT-3 (23), and time
course data on SOCS-3 expression (24). We used data from
our laboratory to fit the kinetics of c-Fos induction and the
return of c-Fos to basal levels (see Supplementary Figure 4,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38297/abstract). As we
wished to use stochastic as well as deterministic simulations,
we needed to use low numbers of molecules so that multiple
simulations could be performed in reasonable time frames. We
therefore used values in the region of 0–200 for basal expres-
sion, with levels increasing to 500–30,000 after cytokine-
induced up-regulation. In a deterministic simulation, the level
of the mRNA or protein remains fixed under basal conditions,
but in a stochastic simulation, the levels may fluctuate around
the mean value (compare Supplementary Figure 5 [available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38297/abstract] with Figure
1). The level of MMP-1 (mRNA) is often 10-fold higher than
that of MMP-13 (25). Thus, assuming equal degradation rates
for MMP-1 and MMP-13 mRNA, we set the transcription rate
of MMP-1 at 10 times higher than that of MMP-13.
Model validation. The model was validated using ex-
perimental data that were not used in construction of the
model (26,27). The details are given in Supplementary Figure
9 and Supplementary Table 7 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38297/abstract).
Simulated treatments and interventions. The inte-
grated model was used to assess possible therapeutic interven-
tions, since cartilage breakdown does not occur in any of the
individual submodels. We mimicked the addition of cytokines
and MMP activator by altering the initial values of IL-1, OSM,
and/or MMP activator before running the simulations (see
Supplementary Table 4). Details of the species and parameters
used to simulate possible interventions are shown in Supple-
mentary Table 5 (Supplementary Tables 4 and 5 available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38297/abstract).
Figure 1. Simulation results showing the effect of interleukin-1 (IL-1) and/or oncostatin M (OSM) on the expression of matrix metalloproteinase
1 (MMP-1), MMP-13, and tissue inhibitor of metalloproteinases 1 (TIMP-1), using a simulated time period of 48 hours. Curves show the level of
MMP-1 mRNA, MMP-13 mRNA, TIMP-1 mRNA, and collagen fragments. A, Effect of IL-1 alone. B, Effect of OSM alone. C, Effect of IL-1 plus
OSM. Note that in B, MMP-1, MMP-13, and collagen levels are all zero; thus, the individual lines are not visible.
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Modeling tools. We carried out all the deterministic
simulations using the COPASI software tool (28). Stochastic
simulations were carried out on a computer cluster using
the Gillespie algorithm (direct method) (29) and code devel-
oped by staff members of Newcastle University (30). We
analyzed the model output using the R statistical programming
language, and created the graphs using the R package ggplot2
(31). Network figures were constructed in CellDesigner (32)
using the standard Systems Biology Graphical Notation
(SBGN) (33).
Previous experimental data used for constructing
model. Human T/C-28a4 chondrocytes were stimulated with
IL-1 (1 ng/ml), OSM (10 ng/ml), or IL-1 (1 ng/ml) plus OSM
(10 ng/ml). The test reagents were added to the medium at the
start of the experiment, and cells were harvested at different
time points thereafter (4, 8, 12, 24, 48, and 72 hours) (4).
RESULTS
IL-1 and OSM have synergistic effects on
MMP-1, MMP-13, and TIMP-1 expression and collagen
release. Simulations were performed for 48 hours (vir-
tual time) to examine the kinetics of MMP-1, MMP-13,
and TIMP-1 induction (Figure 1). No collagen release
occurred at this time point. In the model, addition of
IL-1 alone led to an increase in MMP-1 expression,
which peaked at 12 hours, but there was no induction
of TIMP-1 above basal levels (Figure 1A). The addition
of OSM alone led to an early induction of TIMP-1,
which peaked at2–4 hours and then slowly returned to
basal levels; however, there was no induction of MMP-1
or collagen release (Figure 1B).
Modeling the addition of IL-1 and OSM together
led to a synergistic induction of MMP-1, which peaked at
8 hours, with levels being 20-fold higher than those
seen with IL-1 alone (Figure 1C). There was also a lower
induction of TIMP-1 than was modeled with OSM
alone. The simulation output showed that the level of
MMP-13 was 10 times lower than that of MMP-1
throughout the time course, as demonstrated experi-
mentally (25). These results compare well to the exper-
imental data whereby human T/C-28a4 chondrocytes
were stimulated with IL-1, OSM, or IL-1 plus OSM
(see Methods for details) (4). Therefore, our model
assumption that c-Jun homodimers have very low tran-
scriptional activity compared to c-Fos/c-Jun heterodimers
produces results that are consistent with the experimen-
tal data.
Simulated addition of MMP activator leads to
collagen release in the presence of IL-1 plus OSM.
Further simulations were performed over a 14-day pe-
riod to examine the kinetics of collagen release with and
without the addition of MMP activator (Figure 2). In the
absence of MMP activator, the model output showed
that0.03% of collagen was released (by MMPs) by day
14 due to low basal levels of MMP activator following
the addition of IL-1 plus OSM (Figure 2A). However,
aggrecan was cleaved by ADAMTS-4, with 87% re-
leased by day 14. If an activator of collagenases was
added at the start of the simulation, then proMMPs were
Figure 2. Simulation results showing the effect of an MMP-activating
protease on the activation of MMPs and on collagen release, using a
simulated time period of 14 days. Curves show the levels of active
MMP-1 protein, active MMP-13 protein (scaled by a factor of 10), and
collagen fragments. In each simulation, both IL-1 and OSM were
added. A, Effect without MMP activator. B, Effect with addition of
MMP activator. See Figure 1 for definitions.
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processed at a much greater rate, and by day 14, 10% of
collagen was released in the model (Figure 2B). The rate
of aggrecan release was not affected by the addition of
MMP activator.
The model was used to assess therapeutic inter-
vention points for the prevention of cytokine-induced
cartilage breakdown. In order to assess the effects of
potential therapeutic interventions, we used the model
with IL-1 plus OSM and high levels of activating pro-
tease, such that collagen release occurred. We ran
simulations for a time period of 14 days and compared
the levels of aggrecan and collagen fragments with
different simulated doses of each treatment/addition.
IL-1 receptor antagonist is predicted to have only
limited beneficial effects. The model predicted that very
high levels of IL-1R antagonist (IL-Ra) would need to
be added for there to be any significant effect on
collagen release (100 times more antagonist than IL-1
receptors). This is because even low levels of IL-1R
binding to IL-1 could initiate signaling, which eventually
led to downstream events that culminated in collagen
release. Thus, the model predicted that this intervention
may delay or slow down collagen release, but cannot
prevent initiation of the disease process. It is therefore
likely that such an intervention used alone would not be
very beneficial (Figure 3A).
OSMR antagonist is predicted to be less effective
than IL-1 receptor antagonist. The model predicted that
the addition of OSMR antagonists would be much less
effective than IL-1R antagonists (Figure 3B). It was
necessary to increase the ratio of OSMR antagonist by
107 to have the same effect as a ratio of 103 for IL-1Ra.
This is because even low levels of OSMR binding to
OSM can lead to the synergistic effect of IL-1 and OSM.
The simultaneous addition of IL-1 and OSMR antago-
nists at the same concentration did not significantly
reduce the levels of aggrecan and collagen fragments as
compared to using IL-1Ra alone (see Supplementary
Table 6, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
38297/abstract).
JAK-1 inhibition is ineffective as an intervention to
reduce collagen release. In the model, JAK-1 phosphor-
ylated only STAT-3, and so to simulate inhibition of this
kinase, we varied the value of the parameter for STAT-3
phosphorylation (kphosSTAT3) from 0 (100% inhibition)
to 0.005 (no inhibition). The effect of 100% inhibition
was marked by a reduction in collagen release, from
10% to 1% on day 14, and a reduction in aggrecan
release, from 87.5% to 1.0% (Figure 4A). However,
Figure 3. Simulation results for interventions with interleukin-1
receptor (IL-1R) or oncostatin M receptor (OSMR) antagonists, using
a simulated time period of 14 days. Simulated conditions consisted of
IL-1 plus OSM plus matrix metalloproteinase activator. Curves show
the percentage of aggrecan and collagen degraded. A, Effect of IL-1R
antagonist. B, Effect of OSMR antagonist. Arrows in A and B show the
direction of increase in the ratio of receptor antagonist to receptor (1,
10, 100, 1,000).
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90% inhibition did not lead to any significant reduction
in collagen release, and even 98% inhibition only re-
duced collagen fragments by 1%.
Inhibition of p38 or JNK produces a moderate
reduction in collagen release. We simulated the inhibition
of p38. In our model, p38 was induced by IL-1 due to
phosphorylation by IRAK-2/TRAF6; however, it then
acted in the OSM/STAT pathway by subsequently phos-
phorylating c-Fos, which bound phosphorylated c-Jun to
form an AP-1 complex (Figure 5). We found that the
model predicted that p38 inhibition had a much greater
effect on collagen release than did JAK-1 inhibition
(Figure 4B). Previously published data, which were not
used in the model construction, demonstrated that p38
inhibition is effective at blocking IL-1–stimulated carti-
lage collagen release (34). JNK is phosphorylated by
IRAK-2/TRAF6, and phosphorylated JNK subsequently
phosphorylates c-Jun. The model predicted that inhibi-
tion of JNK, by reducing the rate of kphoscFos from 0 to
100%, led to a reduction in collagen release (Figure 4C),
and similar to p38, this was a more effective intervention
than JAK-1 inhibition (Figure 4A). In order to confirm
this prediction, we conducted an in vitro experiment in
which we cultured cytokine-stimulated cartilage in the
presence of a JNK inhibitor, and showed that cartilage
collagen release was almost completely blocked by the
JNK inhibitor SP600125 (Figure 4D).
Overexpression of TIMP-3 has a greater beneficial
effect than overexpression of TIMP-1. To simulate over-
expression of TIMP-1 or TIMP-3, we varied the initial
amount of protein from 200 to 200,000 molecules, with 3
intervals on a logarithmic scale (Figure 6). TIMP-1
overexpression delayed the onset of aggrecan and colla-
gen release but only slightly reduced the maximum
amount of degradation by day 14 (Figure 6A). Interest-
ingly, TIMP-3 overexpression led to a much greater
delay in aggrecan release and decreased the amount of
collagen release by day 14 (Figure 6B).
Figure 4. Simulation results showing the effect of inhibiting JAK-1, JNK, or p38 activity, using a simulated time period of 14 days. Simulated
conditions consisted of IL-1 plus OSM plus MMP activator. Curves show the percentage of aggrecan and collagen degraded. A, Effect of JAK-1
inhibition. B, Effect of p38 inhibition. Arrows show the direction of increase (0–100%, in steps of 10; kphoscFos  5  10
–7, 4.5  10–7, 4  10–7, . . . ,
0) molecules1 seconds1). C, Effect of JNK inhibition. Arrows show the direction of increase (0–100%, in steps of 10; kphoscJun  1  10
–4, 9 
10–5, 8  10–5, . . . , 0 molecules1 seconds1). D, Effect of JNK inhibition on IL-1 plus OSM–induced cartilage breakdown. Bovine nasal cartilage
discs were cultured in the presence of IL-1 (0.5 ng/ml) plus OSM (10 ng/ml) in the presence or absence of the JNK inhibitor SP600125 (SP; 30 M)
or DMSO control. Medium was removed on day 7, and fresh reagents added. On day 14, the medium was removed, and the remaining cartilage was
papain digested. The hydroxyproline assay was used to measure the release of collagen into the medium on day 7 and day 14. Values are the mean
SEM of data accumulated from a minimum of 2 different experiments of a total of 4 experiments conducted.   P  0.01 for cytokine treatment
versus cytokine plus inhibitor treatment, by t-test. See Figure 1 for definitions.
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Stochastic effects are important and have impli-
cations for treatments. It is known that stochastic effects
are important in biologic systems, may partly explain the
cellular heterogeneity observed in experimental systems,
and similarly account for the observed differences in loss
of cartilage collagen in patients, in that some patients
experience rapid joint destruction while others have
relatively slow progression. Factors such as age at dis-
ease onset, severity of symptoms, and response to treat-
ments also further contribute to etiology. Therefore, we
also ran the model using stochastic simulation.
We first compared the output for MMP and
TIMP-1 expression over 48 hours with different cytokine
treatments and found that although the mean behavior
was similar to that of the deterministic model, there was
large variability in the expression of MMP-1 mRNA
when both IL-1 and OSM were added (see Supplemen-
tary Figure 5, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38297/abstract). The level of MMP-1 mRNA was
plotted for 50 individual runs, and as can be seen in
Supplementary Figure 5D, there was considerable vari-
ation in the amount of induction and in the timing of
maximal induction. We also ran the model with IL-1 plus
OSM with the addition of MMP activator for a simu-
lated time of 14 days. The model predicted a lot of
variability in the levels of active MMPs and, hence,
variation also in the percentage of collagen released by
day 14 (see Supplementary Figure 6). The mean values
of 200 stochastic simulations were fairly similar to the
deterministic output, although slightly higher values of
active MMPs and collagen release were obtained with
the stochastic model.
To examine the role of stochastic effects in
possible treatments, we carried out stochastic simulation
for the TIMP-1 and TIMP-3 overexpression interven-
tion. The model predicted that TIMP-1 overexpression
(103 or more) may significantly delay collagen release
but that there would be only a small reduction in the
amount of collagen release by day 14 (see Supplemen-
Figure 5. Simplified network diagram showing the involvement of JNK and p38 in the system. Interleukin-1 (IL-1) activates tumor necrosis factor
receptor–associated factor 6 (TRAF6), which phosphorylates both p38 and JNK. JNK phosphorylates c-Jun, and p38 phosphorylates c-Fos, which
has been up-regulated via the oncostatin M (OSM)/JAK-1/STAT-3 signaling pathway. Phosphorylated c-Fos binds to phosphorylated c-Jun to form
the activator protein 1 (AP-1) complex. See Supplementary Figures 1 and 2 for diagrams showing all of the reactions (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38297/abstract).
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tary Figure 7A, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38297/abstract). Conversely, TIMP-3 overexpression
(102 or more) both significantly delayed and reduced
the amount of collagen release (see Supplementary
Figure 7B). These results are consistent with the deter-
ministic model and could imply that stochastic effects
are not important. However, as in the case of no
treatments, there was a lot of individual variation in
collagen release (as evidenced experimentally [see refs.
3–5]), which could be seen when examining individual
simulations (see Supplementary Figure 8). However,
with TIMP-3 overexpression, the variability declined
with increasing levels of TIMP-3, suggesting that colla-
gen release was consistently reduced by this interven-
tion.
DISCUSSION
We developed a mathematical model of some of
the pathways involved in cartilage degradation based on
experimental data from human chondrocytes stimulated
with the cytokines IL-1 and/or OSM. The model in-
cluded sufficient components to explain the synergistic
effects of IL-1 and OSM on MMP expression and the
antagonistic effects of IL-1 and OSM on TIMP-1 expres-
sion (4). The model was also validated using other data
on components of the signaling pathways that are tran-
siently activated in response to cytokines. Since arthritis
is characterized by irreversible loss of ECM, we also
wanted to include collagen and aggrecan degradation in
the model.
The addition of cytokines by themselves is not
sufficient for collagen breakdown and the release of
collagen fragments, since MMPs are synthesized in an
inactive form. Activation of proMMPs is mediated by
proteases, and activation has been shown to be a key
control point in terms of collagenolysis in arthritic
cartilage (6). Therefore, we included the addition of a
collagenase-activating protease, which we named MMP
activator, in our model. We parameterized the model so
that when a collagenase-activating protease is included,
10% of collagen is degraded by day 14 after stimula-
tion with IL-1 plus OSM, as seen with human cartilage
explants (35). We then used the model to simulate
various possible interventions, and we examined the
effect of these on collagen release.
Our model predicted that the use of receptor
inhibitors may not be beneficial because antagonistic
Figure 6. Simulation results showing model predictions for the
overexpression of TIMP-1 or TIMP-3 protein, using a simulated time
period of 14 days. Simulated conditions consisted of IL-1 plus OSM
plus MMP activator. Curves show the percentage of aggrecan and
collagen degraded. A, Effect of TIMP-1 overexpression. B, Effect of
TIMP-3 overexpression. Arrows in A and B show the direction of
increase (2  102, 2  103, 2  104, 2  105 molecules). See Figure 1
for definitions.
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receptors do not totally stop the initial signal and
because, following receptor activation, downstream sig-
naling is rapid, leading to transcription of target genes
such as ADAMTS and MMPs. This prediction was
confirmed by published data showing that IL-1Ra inhib-
its collagen release in tissue from some patients but not
from others (36), which confirms that this may not be a
useful approach by itself. OSMR antagonists have only
recently been developed and have not yet been tested
experimentally in a cartilage breakdown model, so these
model predictions will be tested when reagents are
available.
Simulated blocking of JAK-1 activity, one of the
first kinases in the signaling pathways, was not effective
unless 100% inhibition was achieved. With 100% inhi-
bition, there was no phosphorylation of STAT-3, so
there was no up-regulation of c-Fos. This means that
there were only low levels of ADAMTS, MMPs, and
MMP activator, which are insufficient to cause collagen
release. However, 100% inhibition is unlikely in the
clinical setting, and so this intervention may not be very
beneficial if administered alone. The prediction for the
effect of JAK-1 inhibition on collagen release is yet to be
tested in an experimental setting.
Interestingly, the model predicted that inhibition
of p38 or JNK activity would be much more effective, as
this decreased the amount of phosphorylated c-Jun and
c-Fos, respectively, and so inhibited the formation of
AP-1 transcription factor complexes. Inhibiting p38 was
predicted to be slightly more effective than inhibiting
JNK, as this reduced the formation of the more tran-
scriptionally active AP-1 complex, consisting of c-Fos/c-
Jun heterodimers. Previous experimental data (not used
in the construction of the model) confirmed that p38
inhibition reduces collagen release in a bovine model of
cartilage breakdown (34). In this study, we experimen-
tally explored the effectiveness of JNK inhibition, as
predicted by the model, and showed that this was indeed
effective. However, the JNK inhibitor we used is not
entirely specific, so it is not possible to conclude that
these effects were solely due to JNK inhibition, although
the results confirm the usefulness of computational
models to predict effective interventions.
The model was also used to mimic the overex-
pression of TIMP-1 or TIMP-3 protein. Although we
assumed that TIMP-1 mainly inhibits MMPs, whereas
TIMP-3 mainly inhibits ADAMTS-4, the model pre-
dicted that TIMP-3 overexpression would have a greater
effect on reducing collagen release (Figure 5). This was
due to our assumption that aggrecan protects collagen
from degradation, and the delay in aggrecan release
meant that collagen was not accessible for degradation
during the time period when MMP-1 and MMP-13 are
most active. Therefore, the model suggested that target-
ing aggrecan release, especially if the intervention is
performed at the appropriate time window, is a promis-
ing strategy to investigate further. Our predictions are
supported by experimental data showing limited benefit
from overexpressing TIMP-1 in a mouse model of
arthritis (37). Direct inhibition of MMPs with low mo-
lecular weight inhibitors proved to be ineffective in
patients, as off-target effects were identified (38).
Although we mainly used deterministic simula-
tions in this study, stochastic effects are an important
consideration in biologic systems. Our model predicted
that the response to IL-1 plus OSM was variable in terms
of the levels of active MMPs and collagen release (see
Supplementary Figures 6 and 7, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38297/abstract). Stochastic
simulations for TIMP-1 and TIMP-3 overexpression
generated average behaviors that were similar to those
in the deterministic model. TIMP-3 overexpression was
much more effective, significantly delaying and reducing
collagen release. Although individual simulation results
exhibited considerable variability, this was reduced with
increasing amounts of TIMP-3 overexpression, which
suggests that this treatment is effective at reducing
collagen release.
Our model represents a substantial contribution
to the development of a systems approach to ECM
breakdown, using cartilage as a reference tissue. This
tissue is ideal for modeling studies, as it contains a single
cell type. The current model is comprehensive, but we
used a modeling approach that is very amenable to
adding further details and making modifications as
subsequent experimental data and new hypotheses
emerge. For example, we are aware that there is cross-
talk between signaling pathways, that other cytokines
can initiate cartilage breakdown, and that other path-
ways or levels of control (e.g., the role of noncoding
RNAs such as microRNAs and their effect on mRNA
stability) are implicated, none of which were included in
the model. As new experimental data become available,
our model can be extended and refined. However, the
guiding principle for building models is to capture the
essential details without burdening the model with non-
essential details (17). For example, we modeled protein
synthesis of some proteins (DUSP-1, MMP activator,
MKP-1, PP-4, PTPRT, and Sp-1) as one step, omitting
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details of transcription, where we did not have data
concerning mRNA levels.
The predictions generated by the present model
are interesting in that intervention at the level of the
receptors had little effect. This is supported by the fact
that treatment of rheumatoid arthritis patients with
IL-1Ra showed only modest beneficial effects (39).
Increasing the level of TIMP-1 was equally ineffective,
which confirms the data generated when direct inhibi-
tion with MMP inhibitors proved to be ineffective in
patients and affected other tissues of the joint as well
(38). The results with TIMP-3 could suggest that inhibi-
tion of the ADAMTS family could be effective in
patients. Although this treatment would target aggrecan-
degrading enzymes, a reduction in aggrecan release also
helps to prevent irreversible collagen release, since
collagen is inaccessible to MMPs when protected by
aggrecan. Interventions that prevent the transcription of
collagenases, particularly by interfering with JNK signal-
ing pathways, had a much greater effect, and we have
validated this prediction experimentally, confirming that
this pathway may represent tractable therapeutic targets
(40).
In conclusion, there is a great need to increase
our understanding of the molecular mechanisms in-
volved in cartilage release and to develop new interven-
tions (19). We have shown that computer modeling is an
ideal tool to assist in these processes, and there is great
potential for future developments of this approach.
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Errata
DOI 10.1002/art.38635
In this article by Wang et al in the June 2013 issue of Arthritis & Rheumatism (pages 1530–1540), lentivirus
titration protocols were described incorrectly in the two sentences of the “Construction of lentivirus-
mediated miR-29a precursor and inhibitor expression vectors” paragraph of Materials and Methods. These
sentences should have read “Lentivirus particles were concentrated by ultracentrifugation, and lentiviral
genomic RNA was measured by quantitative RT-PCR using LentiX qRT-PCR Titration kits according to the
instructions of the manufacturer (Clontech). Lentivirus titers were calculated and expressed as infectious
units/ml.”
DOI 10.1002/art.38626
In the article by Lauvsnes et al in the December 2013 issue of Arthritis & Rheumatism (pages 3209–3217), a
character was missing from the reported sequence of the synthetic decapeptide mentioned in the “Anti-NR2
antibodies in blood” and “Anti-NR2 antibodies in CSF” paragraphs of Patients and Methods. The correct
sequence is DWEYSVWLSN.
We regret the errors.
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